Discussion: ALK translocations, most commonly involving chromosome 2 translocations resulting in EML4-ALK fusion, occur in approximately 3% to 5% of lung adenocarcinomas. Therapies targeting the ALK tyrosine kinase have been well studied in patients with ALK-rearranged NSCLC. The first generation ALK-tyrosine kinase inhibitor, crizotinib, was approved for use in ALK-rearranged NSCLC in 2011 based on the PROFILE 1001 study and received full United States Food and Drug Administration approval after... Conclusion: In summary, to the authors' knowledge, this is the first published case of a patient with ALK-rearranged ALCL successfully treated with alectinib. Given the rapid progression and the significant neurologic toxicities related to the primary treatment with CHOEP, our patient had limited second-line treatment options. Within 2 months of therapy with alectinib, he experienced resolution of fever and had an impressive and sustained radiographic response on PET/CT imaging, which allowed him to... READ ARTICLE
Clinical Lymphoma Myeloma and Leukemia DOI:10.1016/j.clml.2019.03.001
Authors: Daniel R. Reed, Richard D. Hall, Ryan D. Gentzler, Leonid Volodin, Michael G. Douvas, Craig A. Portell